Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$196.79−10.01 (-4.84%)
Close on Nov 18, 2026Market cap $78.57BP/E –Yield –
Moderna Days Away, Restricted, or Transferred Rate by Year
Days Away, Restricted, or Transferred Rate (DART, per 200,000 hours)
Moderna Days Away, Restricted, or Transferred Rate: 0.18 in FY2025, up 28.6% from a year earlier.
Latest, FY2025
0.18
Period ended Dec 31, 2025
Change on a year earlier
+28.6%
0.14 in FY2024
History
3 years
Since FY2023
Sources
1
2025 Impacting Human Health Report
Where the FY2025 figure comes from
“0.10 0.14 0.18”
Source: 2025 Impacting Human Health Report ↗
Reported in Moderna 2025 Impacting Human Health Report.
annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Days Away, Restricted, or Transferred Rate (DART, per 200,000 hours) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0.18 | +28.6% | 2025 Impacting Human Health Report ↗ |
| FY2024 | Dec 31, 2024 | 0.14 | +40.0% | 2025 Impacting Human Health Report ↗ |
| FY2023 | Dec 31, 2023 | 0.10 | – | 2025 Impacting Human Health Report ↗ |
Cite this data
StockData. (2026). Moderna Days Away, Restricted, or Transferred Rate, annual FY2023–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/ehs-dart
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.
See a number that looks wrong?